Amgen plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore, investing approximately $200 million. The facility will initially focus on expanding manufacturing capabilities for monoclonal antibodies, and will be capable of manufacturing both clinical and commercial products. Construction is expected to begin in the next few months, and the site will be staffed with both new recruits and experienced staff.

“Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” said Madhu Balachandran, executive vice president of Operations at Amgen.